Related Experiment Video
Updated: May 9, 2025
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Real-World Experience Using Proton Versus Photon Craniospinal Irradiation for Leptomeningeal Disease
Kelsey M Frechette1, Amanda F Meyer1, Sara B Leier1
1Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Purpose:
Data demonstrate improved survival with proton craniospinal irradiation (CSI) over involved field radiation therapy for leptomeningeal disease (LMD). It is unknown how photon CSI compares in the treatment of LMD. We report our institution's real-world experience using proton versus photon CSI for LMD.
Methods And Materials:
We performed a retrospective review of LMD patients treated with photon or proton CSI from January 2021 to February 2024. All histologies were included. Patient characteristics and complete blood counts were collected before and after CSI. The primary endpoint was serious cytopenia likely caused by CSI. The median overall survival was estimated using the Kaplan-Meier method.
Results:
Thirty-six patients with LMD treated with CSI (27 proton and 9 photon) were included. Across all major cell lines (hemoglobin, platelets, leukocytes, neutrophils, and lymphocytes), the rate of serious (grade 3 or higher) cytopenia likely caused by CSI was not different between the proton and photon groups (p > .21). The median overall survival in the proton and photon groups was 3.0 months and 1.7 months, respectively (hazard ratio, 1.49; p = .47).
Conclusions:
In a single-institutional experience treating LMD, acute cytopenias likely caused by CSI were not different between proton and photon CSI across all major cell lines. Survival was also similar between modalities; therefore, photon CSI may be a safe, efficacious option for LMD.
